Hopes for the leading compound in the CINOD class of arthritis drugs have been dealt a serious blow after it failed to live up to expectations in phase II trials. AstraZeneca may now pull out of its partnership with the drug's developer, NicOx. Although great things had been anticipated for the drug, it now seems highly unlikely that it will challenge the leading COX-II inhibitors.
NicOx has filed a New Drug Application for osteoarthritis treatment naproxcinod to the FDA. While Datamonitor expects a positive decision, the success of the drug will hinge on NicOx obtaining a marketing partner, as the company currently has inadequate resources to commercialize naproxcinod on its own in the competitive and highly genericized US osteoarthritis market.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions